Neurological events reported after COVID-19 vaccines: an analysis of vaccine adverse event reporting system
Objective: To identify the rates of neurological events following administration of mRNA (Pfizer, Moderna) or adenovirus vector (Janssen) vaccines in the U.S. Methods: We used publicly available data from the U.S. Vaccine Adverse Event Reporting System (VAERS) collected between January 1, 2021 and J...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Published: |
John Wiley & Sons
2022
|
| _version_ | 1825938684615065600 |
|---|---|
| author | Frontera, Jennifer A. Tamborska, Arina A. Doheim, Mohamed F. Garcia-Azorin, David Gezegen, Hasim Guekht, Alla Yusof Khan, Abdul Hanif Khan Santacatterina, Michele Sejvar, James Thakur, Kiran T. Westenberg, Erica Winkler, Andrea S. Beghi, Ettore |
| author_facet | Frontera, Jennifer A. Tamborska, Arina A. Doheim, Mohamed F. Garcia-Azorin, David Gezegen, Hasim Guekht, Alla Yusof Khan, Abdul Hanif Khan Santacatterina, Michele Sejvar, James Thakur, Kiran T. Westenberg, Erica Winkler, Andrea S. Beghi, Ettore |
| author_sort | Frontera, Jennifer A. |
| collection | UPM |
| description | Objective: To identify the rates of neurological events following administration of mRNA (Pfizer, Moderna) or adenovirus vector (Janssen) vaccines in the U.S. Methods: We used publicly available data from the U.S. Vaccine Adverse Event Reporting System (VAERS) collected between January 1, 2021 and June 14, 2021. All free text symptoms that were reported within 42 days of vaccine administration were manually reviewed and grouped into 36 individual neurological diagnostic categories. Post-vaccination neurological event rates were compared between vaccine types and to age-matched baseline incidence rates in the U.S. and rates of neurological events following COVID. Results: Of 306,907,697 COVID vaccine doses administered during the study timeframe, 314,610 (0.1%) people reported any adverse event and 105,214 (0.03%) reported neurological adverse events in a median of 1 day (IQR0-3) from inoculation. Guillain-Barre Syndrome (GBS), and cerebral venous thrombosis (CVT) occurred in fewer than 1 per 1,000,000 doses. Significantly more neurological adverse events were reported following Janssen (Ad26.COV2.S) vaccination compared to either Pfizer-BioNtech (BNT162b2) or Moderna (mRNA-1,273; 0.15% vs 0.03% vs 0.03% of doses, respectively, p < 0.0001). The observed-to-expected ratios for GBS, CVT and seizure following Janssen vaccination were ≥1.5-fold higher than background rates. However, the rate of neurological events after acute SARS-CoV-2 infection was up to 617-fold higher than after COVID vaccination. Interpretation: Reports of serious neurological events following COVID vaccination are rare. GBS, CVT and seizure may occur at higher than background rates following Janssen vaccination. Despite this, rates of neurological complications following acute SARS-CoV-2 infection are up to 617-fold higher than after COVID vaccination. ANN NEUROL 2022;91:756–771. |
| first_indexed | 2024-03-06T11:17:07Z |
| format | Article |
| id | upm.eprints-102300 |
| institution | Universiti Putra Malaysia |
| last_indexed | 2024-03-06T11:17:07Z |
| publishDate | 2022 |
| publisher | John Wiley & Sons |
| record_format | dspace |
| spelling | upm.eprints-1023002023-07-10T00:08:09Z http://psasir.upm.edu.my/id/eprint/102300/ Neurological events reported after COVID-19 vaccines: an analysis of vaccine adverse event reporting system Frontera, Jennifer A. Tamborska, Arina A. Doheim, Mohamed F. Garcia-Azorin, David Gezegen, Hasim Guekht, Alla Yusof Khan, Abdul Hanif Khan Santacatterina, Michele Sejvar, James Thakur, Kiran T. Westenberg, Erica Winkler, Andrea S. Beghi, Ettore Objective: To identify the rates of neurological events following administration of mRNA (Pfizer, Moderna) or adenovirus vector (Janssen) vaccines in the U.S. Methods: We used publicly available data from the U.S. Vaccine Adverse Event Reporting System (VAERS) collected between January 1, 2021 and June 14, 2021. All free text symptoms that were reported within 42 days of vaccine administration were manually reviewed and grouped into 36 individual neurological diagnostic categories. Post-vaccination neurological event rates were compared between vaccine types and to age-matched baseline incidence rates in the U.S. and rates of neurological events following COVID. Results: Of 306,907,697 COVID vaccine doses administered during the study timeframe, 314,610 (0.1%) people reported any adverse event and 105,214 (0.03%) reported neurological adverse events in a median of 1 day (IQR0-3) from inoculation. Guillain-Barre Syndrome (GBS), and cerebral venous thrombosis (CVT) occurred in fewer than 1 per 1,000,000 doses. Significantly more neurological adverse events were reported following Janssen (Ad26.COV2.S) vaccination compared to either Pfizer-BioNtech (BNT162b2) or Moderna (mRNA-1,273; 0.15% vs 0.03% vs 0.03% of doses, respectively, p < 0.0001). The observed-to-expected ratios for GBS, CVT and seizure following Janssen vaccination were ≥1.5-fold higher than background rates. However, the rate of neurological events after acute SARS-CoV-2 infection was up to 617-fold higher than after COVID vaccination. Interpretation: Reports of serious neurological events following COVID vaccination are rare. GBS, CVT and seizure may occur at higher than background rates following Janssen vaccination. Despite this, rates of neurological complications following acute SARS-CoV-2 infection are up to 617-fold higher than after COVID vaccination. ANN NEUROL 2022;91:756–771. John Wiley & Sons 2022-03-02 Article PeerReviewed Frontera, Jennifer A. and Tamborska, Arina A. and Doheim, Mohamed F. and Garcia-Azorin, David and Gezegen, Hasim and Guekht, Alla and Yusof Khan, Abdul Hanif Khan and Santacatterina, Michele and Sejvar, James and Thakur, Kiran T. and Westenberg, Erica and Winkler, Andrea S. and Beghi, Ettore (2022) Neurological events reported after COVID-19 vaccines: an analysis of vaccine adverse event reporting system. Annals of Neurology, 91 (6). 756- 771. ISSN 0364-5134 https://onlinelibrary.wiley.com/doi/10.1002/ana.26339 10.1002/ana.26339 |
| spellingShingle | Frontera, Jennifer A. Tamborska, Arina A. Doheim, Mohamed F. Garcia-Azorin, David Gezegen, Hasim Guekht, Alla Yusof Khan, Abdul Hanif Khan Santacatterina, Michele Sejvar, James Thakur, Kiran T. Westenberg, Erica Winkler, Andrea S. Beghi, Ettore Neurological events reported after COVID-19 vaccines: an analysis of vaccine adverse event reporting system |
| title | Neurological events reported after COVID-19 vaccines: an analysis of vaccine adverse event reporting system |
| title_full | Neurological events reported after COVID-19 vaccines: an analysis of vaccine adverse event reporting system |
| title_fullStr | Neurological events reported after COVID-19 vaccines: an analysis of vaccine adverse event reporting system |
| title_full_unstemmed | Neurological events reported after COVID-19 vaccines: an analysis of vaccine adverse event reporting system |
| title_short | Neurological events reported after COVID-19 vaccines: an analysis of vaccine adverse event reporting system |
| title_sort | neurological events reported after covid 19 vaccines an analysis of vaccine adverse event reporting system |
| work_keys_str_mv | AT fronterajennifera neurologicaleventsreportedaftercovid19vaccinesananalysisofvaccineadverseeventreportingsystem AT tamborskaarinaa neurologicaleventsreportedaftercovid19vaccinesananalysisofvaccineadverseeventreportingsystem AT doheimmohamedf neurologicaleventsreportedaftercovid19vaccinesananalysisofvaccineadverseeventreportingsystem AT garciaazorindavid neurologicaleventsreportedaftercovid19vaccinesananalysisofvaccineadverseeventreportingsystem AT gezegenhasim neurologicaleventsreportedaftercovid19vaccinesananalysisofvaccineadverseeventreportingsystem AT guekhtalla neurologicaleventsreportedaftercovid19vaccinesananalysisofvaccineadverseeventreportingsystem AT yusofkhanabdulhanifkhan neurologicaleventsreportedaftercovid19vaccinesananalysisofvaccineadverseeventreportingsystem AT santacatterinamichele neurologicaleventsreportedaftercovid19vaccinesananalysisofvaccineadverseeventreportingsystem AT sejvarjames neurologicaleventsreportedaftercovid19vaccinesananalysisofvaccineadverseeventreportingsystem AT thakurkirant neurologicaleventsreportedaftercovid19vaccinesananalysisofvaccineadverseeventreportingsystem AT westenbergerica neurologicaleventsreportedaftercovid19vaccinesananalysisofvaccineadverseeventreportingsystem AT winklerandreas neurologicaleventsreportedaftercovid19vaccinesananalysisofvaccineadverseeventreportingsystem AT beghiettore neurologicaleventsreportedaftercovid19vaccinesananalysisofvaccineadverseeventreportingsystem |